Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis

被引:3
|
作者
Topazian, Hillary M. [1 ,2 ]
Schmit, Nora [1 ]
Gerard-Ursin, Ines [1 ]
Charles, Giovanni D. [1 ]
Thompson, Hayley [1 ]
Ghani, Azra C. [1 ]
Winskill, Peter [1 ]
机构
[1] Imperial Coll London, MRC Ctr Global Infect Dis Anal, Sch Publ Hlth, London, England
[2] Imperial Coll London, Fac Med, Sch Publ Hlth, Med Sch Bldg, St Marys Campus, Norfolk Pl, London W2 1PG, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
P; falciparum; Malaria; RTS; S; Malaria vaccine; Mathematical modelling; PLASMODIUM-FALCIPARUM MALARIA; INTERVENTIONS; AFRICA;
D O I
10.1016/j.vaccine.2023.04.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The World Health Organization has recommended a 4-dose schedule of the RTS,S/AS01 (RTS, S) vaccine for children in regions of moderate to high P. falciparum transmission. Faced with limited sup-ply and finite resources, global funders and domestic malaria control programs will need to examine the relative cost-effectiveness of RTS,S and identify target areas for vaccine implementation relative to scale-up of existing interventions. Methods: Using an individual-based mathematical model of P. falciparum, we modelled the cost-effectiveness of RTS,S across a range of settings in sub-Saharan Africa, incorporating various rainfall pat-terns, insecticide-treated net (ITN) use, treatment coverage, and parasite prevalence bands. We compare age-based and seasonal RTS,S administration to increasing ITN usage, switching to next generation ITNs in settings experiencing insecticide-resistance, and introduction of seasonal malaria chemoprevention (SMC) in areas of seasonal transmission. Results: For RTS,S to be the most cost-effective intervention option considered, the maximum cost per dose was less than $9.30 USD in 90.9% of scenarios. Nearly all (89.8%) values at or above $9.30 USD per dose were in settings with 60% established bed net use and / or with established SMC, and 76.3% were in the highest PfPR2-10 band modelled (40%). Addition of RTS,S to strategies involving 60% ITN use, increased ITN usage or a switch to PBO nets, and SMC, if eligible, still led to significant marginal case reductions, with a median of 2,653 (IQR: 1,741 to 3,966) cases averted per 100,000 people annually, and 82,270 (IQR: 54,034 to 123,105) cases averted per 100,000 fully vaccinated children (receiving at least three doses). Conclusions: Use of RTS,S results in reductions in malaria cases and deaths even when layered upon exist-ing interventions. When comparing relative cost-effectiveness, scale up of ITNs, introduction of SMC, and switching to new technology nets should be prioritized in eligible settings. (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:3215 / 3223
页数:9
相关论文
共 50 条
  • [1] Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa
    Galactionova, Katya
    Tediosi, Fabrizio
    Camponovo, Flavia
    Smith, Thomas A.
    Gething, Peter W.
    Penny, Melissa A.
    [J]. VACCINE, 2017, 35 (01) : 53 - 60
  • [2] Assessment of the RTS,S/AS01 malaria vaccine
    Moorthy, V. S.
    Newman, R. D.
    Duclos, P.
    Okwo-Bele, J. M.
    Smith, P. G.
    [J]. LANCET INFECTIOUS DISEASES, 2013, 13 (04): : 280 - 282
  • [3] Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi
    Bell, Griffin J.
    Loop, Matthew
    Topazian, Hillary M.
    Hudgens, Michael
    Mvalo, Tisungane
    Juliano, Jonathan J.
    Kamthunzi, Portia
    Tegha, Gerald
    Mofolo, Innocent
    Hoffman, Irving
    Bailey, Jeffrey A.
    Emch, Michael
    [J]. VACCINE, 2020, 38 (25) : 4079 - 4087
  • [4] Implementation of the malaria candidate vaccine RTS,S/AS01
    Greenwood, Brian
    Doumbo, Ogobara K.
    [J]. LANCET, 2016, 387 (10016): : 318 - 319
  • [5] RTS,S/AS01 malaria vaccine and child mortality
    Aaby, Peter
    Rodrigues, Amabelia
    Kofoed, Poul-Erik
    Benn, Christine Stabell
    [J]. LANCET, 2015, 386 (10005): : 1735 - 1736
  • [6] The history of the RTS,S/AS01 malaria vaccine trial
    Keating, Conrad
    [J]. LANCET, 2020, 395 (10233): : 1336 - 1337
  • [7] The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
    Fortpied, Juliette
    Collignon, Sylvie
    Moniotte, Nicolas
    Renaud, Frederic
    Bayat, Babak
    Lemoine, Dominique
    [J]. MALARIA JOURNAL, 2020, 19 (01)
  • [8] The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
    Juliette Fortpied
    Sylvie Collignon
    Nicolas Moniotte
    Frédéric Renaud
    Babak Bayat
    Dominique Lemoine
    [J]. Malaria Journal, 19
  • [9] Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program
    Baral, Ranju
    Levin, Ann
    Odero, Chris
    Pecenka, Clint
    Bawa, John Tanko
    Antwi-Agyei, Kwadwo Odei
    Amponsa-Achaino, Kwame
    Chisema, Mike Nenani
    Jalango, Rose Eddah
    Mkisi, Rouden
    Gordon, Scott
    Morgan, Winthrop
    Muhib, Farzana
    [J]. VACCINE, 2023, 41 (08) : 1496 - 1502
  • [10] Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study
    Thompson, Hayley A.
    Hogan, Alexandra B.
    Walker, Patrick G. T.
    Winskill, Peter
    Zongo, Issaka
    Sagara, Issaka
    Tinto, Halidou
    Ouedraogo, Jean-Bosco
    Dicko, Alassane
    Chandramohan, Daniel
    Greenwood, Brian
    Cairns, Matt
    Ghani, Azra C.
    [J]. LANCET GLOBAL HEALTH, 2022, 10 (12): : E1782 - E1792